37. EVALUATION OF THE STABILITY OF LYOPHILIZED PLASMA SAMPLE IN THE PROFICIENCY TESTING SCHEME FOR DETECTING ANTIGENS OF NS1 VIRUS DENGUE
Main Article Content
Abstract
Objective: Evaluate the stability of lyophilized plasma items to detect Dengue virus NS1 antigen according to ISO/IEC 17043:2023 and ISO 13528:2022 standards for application in proficiency testing (PT) scheme.
Method: Experimental research. Lyophilized plasma items including 2 batches: batch A (positive samples for Dengue virus NS1 antigen), batch B (negative samples for Dengue virus NS1 antigen) after being checked for homogeneity, will be evaluated for short-term and long-term stability according to ISO 13528. Select a random sample through Microsoft Excel 16 software. Use one-way analysis of variance (One-way ANOVA) to evaluate the homogeneity of the samples.
Results: At short-term conditions (transportation time), the items are stable up to 7 days. At longterm conditions, when stored at -20o C, 0o C, 2 - 8o C, the items are stable up to 90 days.
Conclusion: The lyophilized plasma item to detect Dengue virus NS1 antigen achieved stability during transportation and storage conditions to meet ISO/IEC 17043:2023 and ISO 13528:2022 standards for application in proficiency testing scheme.
Article Details
Keywords
Proficiency testing, NS1, Dengue virus, Dengue fever, stability
References
[2] World Health Organization and Unicef. Handbook for clinical management of Dengue, 2012.
[3] Shrivastava A, Dash PK, Tripathi NK et al, Evaluation of a commercial Dengue NS1 enzyme-linked immunosorbent assay for early diagnosis of dengue infection. Indian J Med Microbiol, 2011; 29(1):51-5.
[4] ISO/IEC 17043:2023 - General requirements for the competence of proficiency testing providers.
[5] ISO 13528:2022 - Statistical methods for use in proficiency testing by interlaboratory comparison.
[6] Ammann C, Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. AAPS PharmSciTech. 2011;12(4):1264-75.
[7] Fryer J, Minhas R, Dougall T et al., Collaborative study to evaluate the proposed WHO 4th international standard for hepatitis B virus (HBV) DNA for nucleic acid amplification technique (NAT)-based assays. World Health Organization. 2016; WHO ECBS Report 2016, WHO/BS/2016.2291:pp. 1-41.
[8] Poe A, Duong NT, Bedi K et al., Stability of hepatitis C virus RNA and anti-HCV antibody in air-dried and freeze-dried human plasma samples. J Virol Methods. 2018;253:53-5.